Open | $2.300 |
Close | $2.130 |
Volume / Avg. | 1.562M / 2.210M |
Day Range | 2.060 - 2.340 |
52 Wk Range | 0.500 - 3.890 |
Market Cap | $396.356M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 46 |
Short Interest | % |
Days to Cover | 15.1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Taysha Gene Therapies (NASDAQ: TSHA) through any online brokerage.
Other companies in Taysha Gene Therapies’s space includes: Renovaro (NASDAQ:RENB), KalVista Pharma (NASDAQ:KALV), Humacyte (NASDAQ:HUMA), Voyager Therapeutics (NASDAQ:VYGR) and Celcuity (NASDAQ:CELC).
The latest price target for Taysha Gene Therapies (NASDAQ: TSHA) was reported by Needham on Thursday, February 29, 2024. The analyst firm set a price target for 5.00 expecting TSHA to rise to within 12 months (a possible 135.85% upside). 24 analyst firms have reported ratings in the last year.
The stock price for Taysha Gene Therapies (NASDAQ: TSHA) is $2.12 last updated March 18, 2024 at 6:56 PM EDT.
There are no upcoming dividends for Taysha Gene Therapies.
Taysha Gene Therapies’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Taysha Gene Therapies.
Taysha Gene Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.